NVO241220P117000
- 34.70
- +23.75+216.89%
Novo-Nordisk A/S Newsroom
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Novo Nordisk Bleeding Prevention Injection for Hemophilia Granted FDA Nod
Health Care Roundup: Market Talk
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
FDA Approves Alhemo Injection as Once-daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older With Hemophilia A or B With Inhibitors
Top Gap Ups and Downs on Friday: NVO, BABA, INFY and More
Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Novo-Nordisk A/S Options Spot-On: On December 20th, 195.36K Contracts Were Traded, With 638.38K Open Interest
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ
Friday Market Rebounds Some of Weeks Loss | Wall Street Today
12 Health Care Stocks Moving In Friday's Pre-Market Session
US Equities Markets End Higher Friday as Investors Evaluate Macro Data
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
What's Going On With Amgen Stock On Friday?
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $105
Jefferies Maintains Novo-Nordisk A/S(NVO.US) With Sell Rating, Cuts Target Price to $81.5